Every 10-Q that LeMaitre Vascular, Inc. (LMAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LMAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMAT filings page.
LeMaitre Vascular reported higher results for the quarter and six months ended June 30, 2026. Quarterly net sales were $70.4 million, up 10% year over year, with net income of $17.1 million and diluted EPS of $0.74. For the first half, net sales reached $136.9 million, also up 10%, and net income was $32.7 million with diluted EPS of $1.42. Growth was driven by higher selling prices, increased volumes, and stronger graft and shunt sales, while catheters declined.
Profitability improved, with gross margin rising to 72.1% in the quarter and 72.4% year-to-date, helped by pricing, product mix, and lower shipping costs. At June 30, 2026, cash and cash equivalents were $26.6 million and short-term marketable securities $349.6 million, against $172.5 million of 2.50% convertible senior notes due 2030. Operating cash flow for the first half was $31.1 million. The company paid $0.50 per share in cash dividends year-to-date and has a $100 million share repurchase authorization in place with no repurchases yet.
LeMaitre Vascular, Inc. reported solid first‑quarter 2026 growth with higher sales, margins, and earnings. Net sales rose to $66.6 million, up 11% from 2025, driven by grafts, valvulotomes, and shunts across all regions. Gross profit increased to $48.4 million and gross margin improved to 72.7%, helped by price increases, manufacturing efficiencies, and a more profitable product mix.
Net income grew to $15.7 million, up from $11.0 million, with diluted EPS at $0.68. The company generated $15.1 million of operating cash flow, ending the quarter with $26.9 million in cash and $340.4 million in short‑term marketable securities, alongside $172.5 million of 2.50% convertible senior notes due 2030.
LeMaitre increased its quarterly dividend to $0.25 per share and authorized a $100 million share repurchase program, while continuing to invest in global sales expansion, ERP implementation, and facility leases. Biologics represented 53% of sales, and international markets contributed 44% of net sales, aided by a weaker U.S. dollar and recent regulatory approvals.
LeMaitre Vascular (LMAT) reported Q3 2025 results showing higher sales and earnings. Net sales were $61,046 thousand, up from $54,819 thousand a year ago. Net income rose to $17,362 thousand, and diluted EPS was $0.75 versus $0.49. Gross profit increased to $45,955 thousand as cost of sales declined to $15,091 thousand.
Results included a one‑time Employee Retention Credit benefit recorded in Q3: $4.8 million recognized as reductions to cost of sales ($2.7 million), sales and marketing ($0.8 million), general and administrative ($0.3 million), and research and development ($0.3 million), plus $0.7 million of interest income, and $0.7 million of related professional fees in general and administrative expense. The company did not recognize credits for claims filed for July–September 2021 under the One Big Beautiful Bill Act.
Year‑to‑date operating cash flow was $58,094 thousand. The balance sheet showed cash and cash equivalents of $25,494 thousand and short‑term marketable securities of $317,561 thousand. Convertible senior notes outstanding totaled $172,500 thousand; the conversion rate was adjusted to 8.3637 per $1,000 after a $0.20 per‑share dividend, which continued in Q4.